The Role of Psychostimulants in the Management of Refractory Catatonia: A Comprehensive Review of Case Reports

Background/Objectives: Catatonia is a neuropsychiatric syndrome characterised by motor, behavioural, and affective abnormalities and is frequently associated with mood disorders, particularly major depressive and bipolar disorders. Although benzodiazepines and electroconvulsive therapy are considered first-line treatments, a substantial proportion of patients show partial or no response, especially in chronic, affective, or medically complex presentations. Contemporary neurobiological models implicate dysfunction across multiple neurotransmitter systems, including GABAergic, glutamatergic, and dopaminergic pathways, as well as disturbances in cortico-striato-thalamo-cortical circuits involved in psychomotor control and arousal regulation. Within this framework, psychostimulants may exert therapeutic effects by enhancing dopaminergic and noradrenergic transmission, thereby modulating frontal–striatal networks and facilitating behavioural activation and motor initiation. Evidence from conditions characterised by psychomotor slowing, apathy, and impaired behavioural initiation provides a neurophysiological rationale for their adjunctive use in selected cases of catatonia, particularly when associated with mood disorders. However, there is a dearth of empirical data, with the evidence largely confined to case reports, hence the need for comprehensive reviews of cases and controlled studies to clarify the role of psychostimulants and to explore drug combinations in the treatment of catatonia. Methods: We conducted a comprehensive review of case reports on 22-October-2026 on PubMed, Scopus, PsycInfo/PsycArticles, and Web of Science. Results: We included 9 studies. Psychostimulants were usually helpful in inducing rapid symptoms resolution of catatonia. Conclusions: Psychostimulants may be used in cases of catatonia and provide rapid improvement. Future longitudinal, double-blind designs are likely to allow reliably assessing the value of psychostimulants in catatonia.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-11-18
DOI
https://doi.org/10.3390/ph19111836
Primary Topic
Electroconvulsive Therapy Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Role of Psychostimulants in the Management of Refractory Catatonia: A Comprehensive Review of Case Reports

Delfina Janiri, Silvia Montanari, Alessio Simonetti, Gabriele Sani et al.
Pharmaceuticals
Electroconvulsive Therapy Studies
article

The Role of Psychostimulants in the Management of Refractory Catatonia: A Comprehensive Review of Case Reports

Delfina Janiri, Silvia Montanari, Alessio Simonetti, Gabriele Sani, Stella Margoni, Georgios Demetrios Kotzalidis, Alexia Emilia Koukopoulos, Giovanni Bartolucci, Lorenzo Moccia, Luca Onori, Mario Pinto, Michele Pellegrino
article en

Abstract

Background/Objectives: Catatonia is a neuropsychiatric syndrome characterised by motor, behavioural, and affective abnormalities and is frequently associated with mood disorders, particularly major depressive and bipolar disorders. Although benzodiazepines and electroconvulsive therapy are considered first-line treatments, a substantial proportion of patients show partial or no response, especially in chronic, affective, or medically complex presentations. Contemporary neurobiological models implicate dysfunction across multiple neurotransmitter systems, including GABAergic, glutamatergic, and dopaminergic pathways, as well as disturbances in cortico-striato-thalamo-cortical circuits involved in psychomotor control and arousal regulation. Within this framework, psychostimulants may exert therapeutic effects by enhancing dopaminergic and noradrenergic transmission, thereby modulating frontal–striatal networks and facilitating behavioural activation and motor initiation. Evidence from conditions characterised by psychomotor slowing, apathy, and impaired behavioural initiation provides a neurophysiological rationale for their adjunctive use in selected cases of catatonia, particularly when associated with mood disorders. However, there is a dearth of empirical data, with the evidence largely confined to case reports, hence the need for comprehensive reviews of cases and controlled studies to clarify the role of psychostimulants and to explore drug combinations in the treatment of catatonia. Methods: We conducted a comprehensive review of case reports on 22-October-2026 on PubMed, Scopus, PsycInfo/PsycArticles, and Web of Science. Results: We included 9 studies. Psychostimulants were usually helpful in inducing rapid symptoms resolution of catatonia. Conclusions: Psychostimulants may be used in cases of catatonia and provide rapid improvement. Future longitudinal, double-blind designs are likely to allow reliably assessing the value of psychostimulants in catatonia.

PharmaceuticalsVol. 19(11)
Università Cattolica del Sacro Cuore (IT), Baylor College of Medicine (US), Agostino Gemelli University Polyclinic (IT), Link Campus University (IT)
Good health and well-being
Electroconvulsive Therapy Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon